Allied Investment Advisors LLC Acquires New Holdings in Merck & Co., Inc. (MRK)

Allied Investment Advisors LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 3,670 shares of the company’s stock, valued at approximately $207,000.

Several other institutional investors and hedge funds have also modified their holdings of the company. TCI Wealth Advisors Inc. lifted its holdings in shares of Merck & Co., Inc. by 4.9% during the 4th quarter. TCI Wealth Advisors Inc. now owns 19,347 shares of the company’s stock valued at $1,089,000 after purchasing an additional 903 shares during the last quarter. CIBC World Markets Inc. lifted its holdings in shares of Merck & Co., Inc. by 12.2% during the 4th quarter. CIBC World Markets Inc. now owns 824,996 shares of the company’s stock valued at $46,423,000 after purchasing an additional 89,843 shares during the last quarter. Engineers Gate Manager LP lifted its holdings in shares of Merck & Co., Inc. by 161.6% during the 4th quarter. Engineers Gate Manager LP now owns 20,122 shares of the company’s stock valued at $1,132,000 after purchasing an additional 12,429 shares during the last quarter. Quantitative Systematic Strategies LLC lifted its holdings in shares of Merck & Co., Inc. by 27.6% during the 4th quarter. Quantitative Systematic Strategies LLC now owns 27,572 shares of the company’s stock valued at $1,551,000 after purchasing an additional 5,970 shares during the last quarter. Finally, Private Wealth Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 4.4% during the 4th quarter. Private Wealth Partners LLC now owns 251,890 shares of the company’s stock valued at $14,174,000 after purchasing an additional 10,580 shares during the last quarter. Hedge funds and other institutional investors own 74.60% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 60,000 shares of Merck & Co., Inc. stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total transaction of $3,697,800.00. Following the completion of the transaction, the insider now owns 101,484 shares in the company, valued at approximately $6,254,458.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael J. Holston sold 12,500 shares of Merck & Co., Inc. stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total value of $770,375.00. The disclosure for this sale can be found here. Insiders have sold a total of 82,500 shares of company stock valued at $5,026,025 in the last quarter. Company insiders own 0.25% of the company’s stock.

MRK stock opened at $54.64 on Wednesday. The firm has a market capitalization of $150,096.89, a PE ratio of 58.75, a price-to-earnings-growth ratio of 2.25 and a beta of 0.81. Merck & Co., Inc. has a 52 week low of $53.12 and a 52 week high of $66.41. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.06 and a current ratio of 1.33.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.04. The business had revenue of $10.43 billion during the quarter, compared to analyst estimates of $10.48 billion. Merck & Co., Inc. had a return on equity of 28.61% and a net margin of 6.40%. The company’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the business posted $0.89 EPS. equities research analysts expect that Merck & Co., Inc. will post 4.16 earnings per share for the current fiscal year.

Merck & Co., Inc. announced that its board has approved a share buyback plan on Tuesday, November 28th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 6th. Shareholders of record on Thursday, March 15th will be paid a dividend of $0.48 per share. The ex-dividend date is Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.51%. Merck & Co., Inc.’s payout ratio is currently 206.45%.

MRK has been the subject of a number of research analyst reports. BMO Capital Markets set a $68.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Wednesday, December 13th. ValuEngine upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. Bank of America initiated coverage on Merck & Co., Inc. in a research note on Tuesday, November 28th. They issued a “buy” rating and a $64.00 target price for the company. Deutsche Bank reduced their target price on Merck & Co., Inc. from $62.00 to $59.00 and set a “hold” rating for the company in a research note on Friday, November 24th. Finally, TheStreet lowered Merck & Co., Inc. from a “b” rating to a “c” rating in a research note on Monday, November 27th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and twelve have issued a buy rating to the company. Merck & Co., Inc. presently has a consensus rating of “Hold” and a consensus target price of $66.41.

TRADEMARK VIOLATION NOTICE: “Allied Investment Advisors LLC Acquires New Holdings in Merck & Co., Inc. (MRK)” was originally reported by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.thestockobserver.com/2018/03/21/allied-investment-advisors-llc-acquires-new-holdings-in-merck-co-inc-mrk.html.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply